Acne is one of the most common skin conditions seen in general practice. Acne vulgaris—the most prevalent form—affects more ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for ...

A sebum-selective 1726-nm laser treatment provides year-long control of moderate-to-severe acne across all skin types, with ...

Acne isn't a single condition. It appears in many forms, affects people at different ages, and can be triggered by a range of ...

Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an update. Ascletis Pharma Inc. has completed a pre-New Drug Application consultation with the ...

Discover a study revealing how the seboselective 1726-nm laser delivers safe, long-lasting acne treatment results with improved skin clarity and confidence.

Use of oral spironolactone in women with acne vulgaris was effective and not associated with increased adverse event risk compared with placebo.

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Compared to other acne forms, cystic acne causes the largest and most painful blemishes. It is also the most difficult to ...

Your soft drink habit may be negatively impacting your health—especially if you consume it daily. Here's what to know.